A Major Subset of Mutated CLL Expresses Affinity-selected and Functionally Proficient Rheumatoid Factors

A Major Subset of Mutated CLL Expresses Affinity-selected and Functionally Proficient Rheumatoid Factors

Bibliographic Details
Main Authors:	Jerry Janssen, Naomi Donner, Zhen Li, Thera A.M. Wormhoudt, Koen Wagner, Jeroen E.J. Guikema, C. Ellen van der Schoot, Arnon P. Kater, Ten Feizi, Richard J. Bende, Carel J.M. van Noesel
Format:	Article
Language:	English
Published:	Wiley 2021-04-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/HS9.0000000000000550

Similar Items

Binding of CLL Subset 4 B Cell Receptor Immunoglobulins to Viable Human Memory B Lymphocytes Requires a Distinctive IGKV Somatic Mutation
by: Rosa Catera, et al.
Published: (2017-01-01)

In Vitro 3D Spheroid Culture System Displays Sustained T Cell-dependent CLL Proliferation and Survival
by: Marco V. Haselager, et al.
Published: (2023-09-01)

Functional Differences Between EBV- and CMV-Specific CD8+ T cells Demonstrate Heterogeneity of T cell Dysfunction in CLL
by: Tom Hofland, et al.
Published: (2020-04-01)

S140: IBRUTINIB SENSITIZES CLL CELLS TO VENETOCLAX BY INTERRUPTING TLR9-INDUCED CD40 UPREGULATION AND PROTEIN TRANSLATION
by: Karoline Kielbassa, et al.
Published: (2023-08-01)

P605: IMMUNOGENETICS AND ANTIGEN REACTIVITY PROFILING CONTRIBUTE TO UNRAVELLING THE ONTOGENY OF CLL STEREOTYPED SUBSET #4
by: Anastasia Iatrou, et al.
Published: (2023-08-01)

High-throughput Proteomics Identifies THEMIS2 as Independent Biomarker of Treatment-free Survival in Untreated CLL
by: Paul J. Hengeveld, et al.
Published: (2023-10-01)

JAK–STAT signalling shapes the NF‐κB response in CLL towards venetoclax sensitivity or resistance via Bcl‐XL
by: Marco V. Haselager, et al.
Published: (2023-06-01)

Distinctive Signaling Profiles With Distinct Biological and Clinical Implications in Aggressive CLL Subsets With Stereotyped B-Cell Receptor Immunoglobulin
by: Marina Gerousi, et al.
Published: (2021-11-01)

Generation of functional CLL-specific cord blood CTL using CD40-ligated CLL APC.
by: William K Decker, et al.
Published: (2012-01-01)

Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study.
by: Caroline Holm Nørgaard, et al.
Published: (2018-01-01)

Tracing CLL-biased stereotyped immunoglobulin gene rearrangements in normal B cell subsets using a high-throughput immunogenetic approach
by: Monica Colombo, et al.
Published: (2020-03-01)

P607: A NOVEL LYMPH NODE-MIMICKING 3D CULTURE SYSTEM DISPLAYS LONG-TERM T CELL-DEPENDENT CLL PROLIFERATION AND SURVIVAL
by: M. Haselager, et al.
Published: (2022-06-01)

P620: GENETIC ALTERATIONS AND OUTCOMES WITH FIXED-DURATION IBRUTINIB+VENETOCLAX (IBR+VEN): RESULTS FROM THE PHASE 3 GLOW STUDY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL
by: Arnon Kater, et al.
Published: (2023-08-01)

Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONYResearch in context
by: Thomas Chatzikonstantinou, et al.
Published: (2023-11-01)

Predictors of infection in chronic lymphocytic leukaemia (CLL).
by: Griffiths, H, et al.
Published: (1992)

PB1952: CLL IN AYA
by: Shehab Mohamed, et al.
Published: (2023-08-01)

Current Treatment Options in CLL
by: Moritz Bewarder, et al.
Published: (2021-05-01)

Quality of life in the UK LRF CLL4 trial (on behalf of the UKNCRI CLL Trials Group)
by: Else, M, et al.
Published: (2006)

Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index
by: Yucai Wang, et al.
Published: (2021-08-01)

UK experience of Ofatumumab in refractory B-CLL
by: Varghese, A, et al.
Published: (2011)

P612: CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)-DERIVED T-CELLS HAVE DISTURBED FATTY ACID METABOLISM, POSSIBLY CONTRIBUTING TO T-CELL DYSFUNCTION
by: C. F. Jacobs, et al.
Published: (2022-06-01)

Restricted T cell receptor repertoire in CLL-like monoclonal B cell lymphocytosis and early stage CLL
by: Gonzalo Blanco, et al.
Published: (2018-06-01)

Final results of a randomized trial comparing autotransplant versus wait and watch in 222 patients with CLL in 1(st) or 2(nd) remission (EBMT CLL auto trial / GCLLSG CLL3R trial)
by: McClanahan, F, et al.
Published: (2010)

Ofatumumab retreatment and maintenance in patients with fludarabine-refractory CLL.
by: Osterborg, A, et al.
Published: (2012)

MALT1-dependent cleavage of CYLD promotes NF-κB signaling and growth of aggressive B-cell receptor-dependent lymphomas
by: Marthe Minderman, et al.
Published: (2023-03-01)

P1517: HUMORAL AND CELLULAR IMMUNE RESPONSES TO SARS-COV-2 NATURAL INFECTION OR VACCINATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A STUDY BY ERIC, THE EUROPEAN RESEARCH INITIATIVE ON CLL
by: Alessandro Campanella, et al.
Published: (2023-08-01)

Combinatorial clustering of residue position subsets predicts inhibitor affinity across the human kinome.
by: Drew H Bryant, et al.
Published: (2013-01-01)

NF-kB and the CLL microenvironment
by: Alice O’Donnell, et al.
Published: (2023-03-01)

Glabellar and auricular leukemia cutis in CLL
by: Bradley Steinman, et al.
Published: (2022-11-01)

Critical molecular pathways in CLL therapy
by: Gerardo Ferrer, et al.
Published: (2018-03-01)

Ibrutinib dose modifications in the management of CLL
by: Camille Hardy-Abeloos, et al.
Published: (2020-06-01)

Response to therapy and survival in CLL is influenced by genetic markers. preliminary analysis from the LRF CLL4 trial.
by: Catovsky, D, et al.
Published: (2004)

A comparison of oral and intravenous fludarabine in the LRF CLL4 trial (on behalf of the UKNCRI CLL trials group)
by: Hillmen, P, et al.
Published: (2006)

BTLA Expression in CLL: Epigenetic Regulation and Impact on CLL B Cell Proliferation and Ability to IL-4 Production
by: Lidia Karabon, et al.
Published: (2021-11-01)

Chronic lymphocytic leukemia (CLL) with Reed–Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?
by: Rebecca L. King, et al.
Published: (2022-01-01)

Physiological Fitness and the Pathophysiology of Chronic Lymphocytic Leukemia (CLL)
by: Andrea Sitlinger, et al.
Published: (2021-05-01)

Prognostic factors in the UK LRF CLL4 trial
by: Oscier, D, et al.
Published: (2006)

Prognostic factors in the UK LRF CLL4 trial.
by: Oscier, D, et al.
Published: (2006)

Prognostic factors in the UK LRF CLL4 trial.
by: Oscier, D, et al.
Published: (2005)

Drug sensitivity by TRAC (DISC) assay as a prognostic factor for patient response in untreated CLL: Results from the UK LRF CLL4 trial.
by: Bosanquet, A, et al.
Published: (2006)